Cantor Fitzgerald Comments on MiMedx Group FY2025 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of MiMedx Group in a research report issued on Thursday, October 30th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn $0.33 per share for the year, up from their previous forecast of $0.25. Cantor Fitzgerald has a “Overweight” rating and a $12.00 price objective on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Cantor Fitzgerald also issued estimates for MiMedx Group’s FY2026 earnings at $0.34 EPS.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. MiMedx Group had a return on equity of 28.35% and a net margin of 10.38%.The business had revenue of $67.69 million for the quarter.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average target price of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG opened at $7.52 on Monday. The company’s 50 day moving average price is $7.00 and its two-hundred day moving average price is $6.79. MiMedx Group has a 12-month low of $5.79 and a 12-month high of $10.14. The firm has a market cap of $1.11 billion, a PE ratio of 27.85 and a beta of 1.73. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08.

Institutional Trading of MiMedx Group

Several large investors have recently made changes to their positions in the company. Great Lakes Advisors LLC acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $88,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $1,759,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $84,000. State of Alaska Department of Revenue acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $54,000. Finally, SG Americas Securities LLC boosted its position in shares of MiMedx Group by 419.3% during the 3rd quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock worth $1,130,000 after acquiring an additional 130,769 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.